Compare · LYRA vs RMD
LYRA vs RMD
Side-by-side comparison of Lyra Therapeutics Inc. (LYRA) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LYRA and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD carries a market cap of $33.14B.
- RMD has hit the wire 26 times in the past 4 weeks while LYRA has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 7 for LYRA).
- Company
- Lyra Therapeutics Inc.
- ResMed Inc.
- Price
- -
- -
- Market cap
- -
- $33.14B
- 1M return
- -
- -6.86%
- 1Y return
- -
- -5.97%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 26
- Recent ratings
- 7
- 25
Lyra Therapeutics Inc.
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest LYRA
- Director Smith W Bradford returned 640 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 15-12G filed by Lyra Therapeutics Inc.
- SEC Form 25 filed by Lyra Therapeutics Inc.
- SEC Form 8-K filed by Lyra Therapeutics Inc.
- Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
- SEC Form 8-K filed by Lyra Therapeutics Inc.
- SEC Form 4 filed by Palasis Maria
- SEC Form 4 filed by Cavalier Jason
- SEC Form 10-K filed by Lyra Therapeutics Inc.
- SEC Form EFFECT filed by Lyra Therapeutics Inc.
Latest RMD
- Chairman and CEO Michael J. Farrell was granted 48,136 units of ResMed Common Stock and covered exercise/tax liability with 28,180 units of ResMed Common Stock, increasing direct ownership by 4% to 491,729 units (SEC Form 4) to satisfy withholding obligation
- Director Christopher Delorefice was granted 554 units of ResMed Common Stock, increasing direct ownership by 23% to 2,977 units (SEC Form 4)
- Global General Counsel Michael J Rider was granted 5,587 units of ResMed Common Stock and covered exercise/tax liability with 3,084 units of ResMed Common Stock, increasing direct ownership by 24% to 12,919 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Ronald R Taylor
- Director Harjit Gill was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 10% to 12,013 units (SEC Form 4)
- Director Desney Tan was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 18% to 7,111 units (SEC Form 4)
- Director John Hernandez was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 22% to 6,227 units (SEC Form 4)
- Director Karen Drexler was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 10% to 11,711 units (SEC Form 4)
- Chief Product Officer Justin Leong was granted 10,314 units of ResMed Common Stock (SEC Form 4)
- Director Carol Burt was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 51% to 3,265 units (SEC Form 4)